ARTICLE | Financial News
Trius proposes follow-on
January 18, 2013 1:17 AM UTC
Trius Therapeutics Inc. (NASDAQ:TSRX) said late Thursday that it is planning a follow-on underwritten by Citigroup; Leerink; and Baird. Trius' tedizolid phosphate is in the Phase III ESTABLISH-2 trial...